Clinical Knowledge

Clinical Reference Knowledge

Regulatory Context

The 21st Century Cures Act (2016) and ONC's Interoperability Final Rule (2020) require US healthcare organizations to expose patient data through standardized FHIR APIs. As of 2024, ~70% of US hospitals support FHIR R4 (source: ONC). CMS ties quality measure reporting to reimbursement through programs like MIPS (Merit-based Incentive Payment System) and the Hospital Value-Based Purchasing Program. Failure to report -- or poor performance -- results in payment adjustments of up to 9%.

HIPAA (Health Insurance Portability and Accountability Act) prohibits transmitting Protected Health Information (PHI) to external services without a BAA (Business Associate Agreement). This is the primary reason clinical AI must run locally: cloud LLM APIs are not BAA-covered by default, and even those that offer BAAs (e.g., Azure OpenAI) face institutional resistance from hospital compliance teams.

Common Lab Reference Ranges

These are general adult reference ranges. Values vary by lab, assay, and patient characteristics. Always defer to the performing laboratory's reference range when available via FHIR referenceRange.

When reporting lab values:

• Always flag values outside the normal range with the severity (mild / moderate / severe)
• Note the date of the observation -- a result from 2 years ago has different clinical significance than one from yesterday
• If the FHIR Observation includes a referenceRange, use that instead of the table above

Condition Codes

SNOMED CT Codes (Primary)

ICD-10-CM to SNOMED Crosswalk

When FHIR Condition resources use ICD-10 coding (system http://hl7.org/fhir/sid/icd-10-cm), map as follows:

• E11.* → Type 2 Diabetes (SNOMED 44054006)
• E10.* → Type 1 Diabetes (SNOMED 46635009)
• I10 → Essential Hypertension (SNOMED 38341003)
• I50.* → Heart Failure (SNOMED 84114007)
• N18.* → Chronic Kidney Disease (SNOMED 40055000)

Note: A Condition resource may have both SNOMED and ICD-10 codes in the coding array. Always check all entries, not just coding[0].

CMS Quality Measures

CMS122v12 -- Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)

CMS165v12 -- Controlling High Blood Pressure

CMS135v12 -- Heart Failure: ACEi/ARB/ARNI Therapy for LVEF < 40%

CMS134v12 -- Diabetes: Medical Attention for Nephropathy

Drug Classifications

When checking medication coverage, recognize these drug class groupings. Matching should be case-insensitive partial string matching on the medication name from FHIR medicationCodeableConcept.text or .coding[].display.

Diabetes Medications

Antihypertensives

Statins (HMG-CoA Reductase Inhibitors)

Heart Failure Medications (Guideline-Directed Medical Therapy)

The four pillars of HFrEF therapy (ACC/AHA 2022):

1. ACEi/ARB/ARNI -- sacubitril/valsartan preferred over ACEi/ARB
2. Beta-Blocker -- carvedilol, metoprolol succinate, or bisoprolol only
3. Aldosterone Antagonist -- spironolactone or eplerenone (if eGFR > 30, K+ < 5.0)
4. SGLT2 Inhibitor -- dapagliflozin or empagliflozin (regardless of diabetes status)

Matching Strategy

medication_name = fhir_med_text.lower()

is_on_insulin = "insulin" in medication_name
is_on_glp1 = any(drug in medication_name for drug in
    ["liraglutide", "semaglutide", "dulaglutide", "exenatide", "tirzepatide",
     "victoza", "ozempic", "trulicity", "byetta", "mounjaro", "rybelsus"])
is_on_sglt2 = any(drug in medication_name for drug in
    ["empagliflozin", "dapagliflozin", "canagliflozin", "ertugliflozin",
     "jardiance", "farxiga", "invokana", "steglatro"])
is_on_acei = any(drug in medication_name for drug in
    ["lisinopril", "enalapril", "ramipril", "benazepril", "fosinopril", "quinapril"])
is_on_arb = any(drug in medication_name for drug in
    ["losartan", "valsartan", "irbesartan", "olmesartan", "telmisartan",
     "candesartan", "azilsartan"])
is_on_betablocker = any(drug in medication_name for drug in
    ["metoprolol", "atenolol", "carvedilol", "bisoprolol", "propranolol", "nebivolol"])
is_on_statin = any(drug in medication_name for drug in
    ["atorvastatin", "rosuvastatin", "simvastatin", "pravastatin", "lovastatin"])

Clinical Comorbidity Patterns

Common co-occurring conditions to watch for during analysis:

• Cardiorenal-metabolic overlap: Diabetes + Hypertension + CKD occur together in ~30% of diabetic patients
• Heart failure + CKD: eGFR < 30 limits medication options (spironolactone, SGLT2i dose adjustment)
• Diabetes + CAD: Statin therapy should be high-intensity; GLP-1/SGLT2i have cardiovascular benefit
• Atrial fibrillation + Heart failure: Common pairing; rate control with beta-blocker preferred

Guardrails

• These reference ranges are general guidelines based on published clinical guidelines (ADA, ACC/AHA, KDIGO), not diagnostic criteria
• Never state that a patient "has" a condition based on a lab value alone
• Always include the disclaimer: "This is for informational and research purposes, not clinical decision-making"
• When flagging care gaps, use language like "may warrant review" not "requires treatment"
• Acknowledge that CMS measure logic here is simplified -- production implementations use the full eCQM (electronic Clinical Quality Measure) specifications from CMS
• Lab reference ranges should defer to the performing laboratory's range when available